Mumbai, January 5, 2026: Metropolis Healthcare Limited (NSE: METROPOLIS, BSE: 542650) reported a robust business performance for the quarter ended December 31, 2025, with consolidated revenues recording a strong year-on-year growth of around 26%, supported by sustained demand across preventive healthcare, wellness programs, and specialty diagnostics.
Consolidated Performance Highlights
During Q3 FY26, the company benefited from strong traction in its TruHealth wellness offerings and a sharp rise in specialty testing volumes across both consumer and institutional channels. The expanded high-end test menu under Core Diagnostics and continuous in-house innovation enabled Metropolis to scale its specialty portfolio across its pan-India network.Key Consolidated Metrics Q3 FY26
| Particulars | Q3 FY26 YoY Growth |
|---|---|
| Consolidated Revenue | ~26% |
| TruHealth Wellness Segment | ~35% |
| Specialty Testing Segment | ~33% |
| B2C Revenue | ~18% |
| B2B Revenue | ~37% |
Management indicated that integration of recent acquisitions is progressing well, with synergies translating into improved operational efficiencies and stronger operating leverage. Several acquired entities continued to outperform the company’s average margin profile, while Core Diagnostics margins remained stable compared to the previous quarter.
Standalone Business Performance
On a standalone basis, Metropolis Healthcare reported revenue growth of approximately 15% year-on-year in Q3 FY26, driven by higher patient footfalls, increased test volumes, and a favourable shift in product mix.Standalone Highlights Q3 FY26
| Segment | YoY Growth |
|---|---|
| Standalone Revenue | ~15% |
| TruHealth Wellness | ~23% |
| Specialty Testing | ~16% |
| B2C Revenue | ~14% |
| B2B Revenue | ~16% |
About the Company
Metropolis Healthcare Limited is a leading diagnostic services provider in India, offering a comprehensive portfolio of pathology and specialty testing services. The company operates through a widespread network of laboratories and collection centres across the country and is listed on the NSE and BSE.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.